Laurence E. Burgess

2.0k total citations
31 papers, 880 citations indexed

About

Laurence E. Burgess is a scholar working on Organic Chemistry, Molecular Biology and Physiology. According to data from OpenAlex, Laurence E. Burgess has authored 31 papers receiving a total of 880 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Organic Chemistry, 12 papers in Molecular Biology and 8 papers in Physiology. Recurrent topics in Laurence E. Burgess's work include Asymmetric Synthesis and Catalysis (8 papers), Asthma and respiratory diseases (8 papers) and Chemical Synthesis and Analysis (5 papers). Laurence E. Burgess is often cited by papers focused on Asymmetric Synthesis and Catalysis (8 papers), Asthma and respiratory diseases (8 papers) and Chemical Synthesis and Analysis (5 papers). Laurence E. Burgess collaborates with scholars based in United States, Sweden and Germany. Laurence E. Burgess's co-authors include A. I. MEYERS, David Chantry, Stephen F. Martin, Michael Hartmann, Jeffrey A. Dodge, Andrew C. Allen, David Thomson, Clifford D. Wright, Kevin M. Koch and Ellen R. Laird and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and The Journal of Immunology.

In The Last Decade

Laurence E. Burgess

31 papers receiving 836 citations

Peers

Laurence E. Burgess
Jack A. Kauffman United States
Wayne Vaccaro United States
Jun Nagamine Japan
Thais M. Sielecki United States
Michael Härter Germany
Barbara J. Haertlein United States
Jonathan S. Foot Australia
Andrew S. Tasker United States
Hitesh J. Sanganee United Kingdom
Patricia D. Pelton United States
Jack A. Kauffman United States
Laurence E. Burgess
Citations per year, relative to Laurence E. Burgess Laurence E. Burgess (= 1×) peers Jack A. Kauffman

Countries citing papers authored by Laurence E. Burgess

Since Specialization
Citations

This map shows the geographic impact of Laurence E. Burgess's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurence E. Burgess with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurence E. Burgess more than expected).

Fields of papers citing papers by Laurence E. Burgess

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurence E. Burgess. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurence E. Burgess. The network helps show where Laurence E. Burgess may publish in the future.

Co-authorship network of co-authors of Laurence E. Burgess

This figure shows the co-authorship network connecting the top 25 collaborators of Laurence E. Burgess. A scholar is included among the top collaborators of Laurence E. Burgess based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laurence E. Burgess. Laurence E. Burgess is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Marx, Matthew A., Brian R. Baer, Joshua A. Ballard, et al.. (2020). Abstract B30: Structure-based drug discovery of MRTX1257, a selective, covalent KRAS G12C inhibitor with oral activity in animal models of cancer. Molecular Cancer Research. 18(5_Supplement). B30–B30. 5 indexed citations
2.
Wenzel, Sally E., David Chantry, Robert W. Hopkins, et al.. (2014). ARRY-502, a potent, selective, oral CRTh2 antagonist reduces Th2 mediators in patients with mild to moderate Th2-driven asthma. European Respiratory Journal. 44(Suppl 58). 4836–4836. 4 indexed citations
3.
Bach, Peter, Jonas Boström, Laurence E. Burgess, et al.. (2013). 5-Alkyl-1,3-Oxazole Derivatives of 6-Amino-Nicotinic Acids as Alkyl Ester Bioisosteres are Antagonists of the P2Y 12 Receptor. Future Medicinal Chemistry. 5(17). 2037–2056. 10 indexed citations
4.
Larsen, Paul D., Yoshiki Shiraishi, Adam W. Cook, et al.. (2011). ARRY-502, A Potent And Selective CRTh2 Antagonist, Affects Basophil And Eosinophil Function Both In Vitro And In Vivo. A4353–A4353. 1 indexed citations
5.
Shiraishi, Yoshiki, Yoo Seob Shin, Laurence E. Burgess, et al.. (2010). Potent and Selective CRTH2 Antagonists are Efficacious in Models of Asthma, Allergic Rhinitis (AR) and Atopic Dermatitis (AD). Journal of Allergy and Clinical Immunology. 125(2). AB124–AB124. 3 indexed citations
6.
Cook, Adam, George Doherty, Kevin J. Hunt, et al.. (2009). Identification and characterization of a potent and selective antagonist of the prostaglandin D2 receptor (94.23). The Journal of Immunology. 182(Supplement_1). 94.23–94.23. 1 indexed citations
7.
Eary, C. Todd, Robert D. Groneberg, Laurence E. Burgess, et al.. (2007). Tetrazole and ester substituted tetrahydoquinoxalines as potent cholesteryl ester transfer protein inhibitors. Bioorganic & Medicinal Chemistry Letters. 17(9). 2608–2613. 74 indexed citations
8.
Allen, Shelley, Benjamin P. Fauber, Aaron S. Anderson, et al.. (2004). Racemic and chiral lactams as potent, selective and functionally active CCR4 antagonists. Bioorganic & Medicinal Chemistry Letters. 14(22). 5537–5542. 30 indexed citations
9.
Allen, Shelley, Aaron S. Anderson, Benjamin P. Fauber, et al.. (2004). Discovery and SAR of trisubstituted thiazolidinones as CCR4 antagonists. Bioorganic & Medicinal Chemistry Letters. 14(7). 1619–1624. 58 indexed citations
10.
Abramsky, Oded, et al.. (2003). Tryptase activates peripheral blood mononuclear cells causing the synthesis and release of TNF-α, IL-6 and IL-1β: possible relevance to multiple sclerosis. Journal of Neuroimmunology. 138(1-2). 115–122. 59 indexed citations
11.
Chantry, David & Laurence E. Burgess. (2002). Chemokines in Allergy. Current Drug Targets - Inflammation & Allergy. 1(1). 109–116. 13 indexed citations
12.
Burgess, Laurence E.. (2000). Mast cell tryptase as a target for drug design. Drug News & Perspectives. 13(3). 147–147. 12 indexed citations
13.
Wright, Clifford D., Andrew M. Havill, Scot Middleton, et al.. (1999). Inhibition of allergen-induced pulmonary responses by the selective tryptase inhibitor 1,5-bis-{4-[(3-carbamimidoyl-benzenesulfonylamino)-methyl]-phenoxy}-pentane (AMG-126737). Biochemical Pharmacology. 58(12). 1989–1996. 51 indexed citations
14.
Hanson, Douglas C., Angela Nguyen, Robert J. Mather, et al.. (1999). UK‐78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage‐gated potassium channel and inhibits human T cell activation. British Journal of Pharmacology. 126(8). 1707–1716. 62 indexed citations
15.
Burgess, Laurence E., Prabha N. Ibrahim, James P. Rizzi, et al.. (1999). Potent selective nonpeptidic inhibitors of human lung tryptase. Proceedings of the National Academy of Sciences. 96(15). 8348–8352. 54 indexed citations
16.
Burgess, Laurence E., Kevin M. Koch, Kelvin Cooper, et al.. (1997). The SAR of UK-78,282: A novel blocker of human T cell Kv1.3 potassium channels. Bioorganic & Medicinal Chemistry Letters. 7(8). 1047–1052. 17 indexed citations
17.
Burgess, Laurence E., et al.. (1996). The preparation of α-substituted, β-hydroxy piperidines and pyrrolidines: The total synthesis of febrifugine. Tetrahedron Letters. 37(19). 3255–3258. 54 indexed citations
18.
Burgess, Laurence E. & A. I. MEYERS. (1992). A simple asymmetric synthesis of 2-substituted pyrrolidines and 5-substituted pyrrolidinones. The Journal of Organic Chemistry. 57(6). 1656–1662. 135 indexed citations
19.
20.
MEYERS, A. I. & Laurence E. Burgess. (1991). ChemInform Abstract: A Simple Asymmetric Synthesis of 2‐Substituted Pyrrolidines from 3‐ Acylpropionic Acids.. ChemInform. 22(34). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jack A. Kauffman Breakdown of academic impact, for papers by Wayne Vaccaro Breakdown of academic impact, for papers by Jun Nagamine Breakdown of academic impact, for papers by Thais M. Sielecki Breakdown of academic impact, for papers by Michael Härter Breakdown of academic impact, for papers by Barbara J. Haertlein Breakdown of academic impact, for papers by Jonathan S. Foot Breakdown of academic impact, for papers by Andrew S. Tasker Breakdown of academic impact, for papers by Hitesh J. Sanganee Breakdown of academic impact, for papers by Patricia D. Pelton
Rankless by CCL
2026